Cancer/testis antigens (CTAs) are a large family of tumor-associated antigens expressed in human tumors of different histological origin, but not in normal tissues, with the exception of the testes and placenta. Numerous immunohistochemical studies have reported associations between CTA expression and a negative estrogen receptor (ER) status in breast tumors, and demonstrated that CTAs are frequently expressed in tumors with higher nuclear grade. The expression of CTAs has not been studied as extensively in ductal carcinoma in situ (DCIS) as it has been in invasive breast cancer. The present retrospective study included archived paraffin-embedded specimens from 83 patients diagnosed with DCIS in the period between January 2007 and December ...
Tumor-specific gene products, such as cancer/testis (CT) antigens, constitute promising targets for ...
Cancer/testis (CT) genes are predominantly expressed in human germ line cells, but not somatic tissu...
Despite significant advances in the treatment of head and neck squamous cell carcinoma (HNSCC), the ...
Background: Cancer-testis (CT) antigens, frequently expressed in human germline cells but not in som...
BACKGROUND: Cancer/testis (CT) antigens are protein antigens normally expressed only in germ cells o...
Background: Cancer-testis antigens (CTA) comprise a family of proteins, which are physiologically ex...
Aim To immunohistochemically evaluate the expression of MAGE-A1, MAGE-A, and NY-ESO-1 cancer/testis...
To determine the expression of cancer testis (CT) genes and antibody responses in a nonselected popu...
A better understanding of the expression of cancer/testis antigens (CTAs) in breast cancer might ena...
Breast cancer remains one of the leading causes of death among women across the world. The last few ...
Breast cancer cells commonly express tumour-associated antigens that can induce immune responses to ...
Recent studies indicate that ER/PR/HER-2-negative (triple-negative, TN) breast cancers may be "CTA-r...
Item does not contain fulltextTo determine the expression of cancer testis (CT) genes and antibody r...
MAGE-C1/CT7, NY-ESO-1, GAGE and MAGE-A4 are members of the cancer/testis (CT) antigen family, which ...
Tumor-specific gene products, such as cancer/testis (CT) antigens, constitute promising targets for ...
Tumor-specific gene products, such as cancer/testis (CT) antigens, constitute promising targets for ...
Cancer/testis (CT) genes are predominantly expressed in human germ line cells, but not somatic tissu...
Despite significant advances in the treatment of head and neck squamous cell carcinoma (HNSCC), the ...
Background: Cancer-testis (CT) antigens, frequently expressed in human germline cells but not in som...
BACKGROUND: Cancer/testis (CT) antigens are protein antigens normally expressed only in germ cells o...
Background: Cancer-testis antigens (CTA) comprise a family of proteins, which are physiologically ex...
Aim To immunohistochemically evaluate the expression of MAGE-A1, MAGE-A, and NY-ESO-1 cancer/testis...
To determine the expression of cancer testis (CT) genes and antibody responses in a nonselected popu...
A better understanding of the expression of cancer/testis antigens (CTAs) in breast cancer might ena...
Breast cancer remains one of the leading causes of death among women across the world. The last few ...
Breast cancer cells commonly express tumour-associated antigens that can induce immune responses to ...
Recent studies indicate that ER/PR/HER-2-negative (triple-negative, TN) breast cancers may be "CTA-r...
Item does not contain fulltextTo determine the expression of cancer testis (CT) genes and antibody r...
MAGE-C1/CT7, NY-ESO-1, GAGE and MAGE-A4 are members of the cancer/testis (CT) antigen family, which ...
Tumor-specific gene products, such as cancer/testis (CT) antigens, constitute promising targets for ...
Tumor-specific gene products, such as cancer/testis (CT) antigens, constitute promising targets for ...
Cancer/testis (CT) genes are predominantly expressed in human germ line cells, but not somatic tissu...
Despite significant advances in the treatment of head and neck squamous cell carcinoma (HNSCC), the ...